Harrow Health, Inc. (HROW)
US — Healthcare Sector
Automate Your Wheel Strategy on HROW
With Tiblio's Option Bot, you can configure your own wheel strategy including HROW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HROW
- Rev/Share 6.7314
- Book/Share 1.2562
- PB 37.2829
- Debt/Equity 5.3572
- CurrentRatio 2.7157
- ROIC 0.0845
- MktCap 1747797407.0
- FreeCF/Share -0.5512
- PFCF -85.3667
- PE -351.4221
- Debt/Assets 0.6937
- DivYield 0
- ROE -0.0896
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HROW | Cantor Fitzgerald | -- | Overweight | -- | $76 | July 11, 2025 |
| Initiation | HROW | BTIG Research | -- | Buy | -- | $62 | June 12, 2025 |
| Initiation | HROW | William Blair | -- | Outperform | -- | -- | June 10, 2025 |
| Initiation | HROW | H.C. Wainwright | -- | Buy | -- | $57 | Feb. 6, 2025 |
| Reiterated | HROW | B. Riley Securities | -- | Buy | $73 | $69 | Dec. 4, 2024 |
News
I Am Loading Up Big Dividends For My Golden Years
HQH,
HROW
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
Innovation, demand, and shortage of providers have kept healthcare inflation significantly higher than the CPI. Regardless of the political scene, the aging U.S. population and rising chronic illnesses are undeniable truths to face. Income investing ensures consistent returns, allowing flexibility in financial planning, despite volatile stock prices.
Read More
About Harrow Health, Inc. (HROW)
- IPO Date 2007-09-28
- Website https://www.harrowinc.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mark L. Baum
- Employees 382
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.